SCIENTIFIC ADVISORY BOARD
Oumeya (Mia) Adjali
Senior Scientist in Gene Therapy, Head of TaRGeT laboratory
INSERM
Olivier Nègre
Chief Scientific Officer
Smart Immune
Jean Christophe Pages
PU-PH Cell biology
Université de Toulouse
Anne Galy
Principal and Founder
RoseBiologics
Dilyana Todorova
Senior Scientist R&D
TreeFrog Therapeutics
Sophie Derenne
Head of Market Analysis and Development Department
EFS
Ana Bejanariu
Sr Principal Scientist I, Project Expert Preclinical Safety R&D Projects France
Sanofi
Hélène Nègre
Head of Market Analysis and Development Department
seqens
Cécile Alanio
Medical Biologist
Hôpital Foch
Senior Scientist
U970-Team10
Adjunct Assistant Professor
UPenn
Régis Gayon
Consultant in Cell and Gene Therapy
Gene Records Consulting
Elsa Abranches
Chief Scientific Officer
ViSync Technologies
Jean-Roch Fabreguettes
Director
MEARY Center
ORGANISATION COMMITTEE
MabDesign, the French biotherapy industrial association, aims to support, federate and increase the visibility of the biopharmaceutical industry, foster exchanges, promote the development and competitiveness of companies, and stimulate innovation by encouraging the emergence of start-ups from academic research.
To achieve its goals MabDesign sets up a coherent set of actions promoting exchanges, collaborations and skills development such as:
– Development of a national directory
– Organization of international scientific events
– Summary reports: ImmunoWatch & BioprocessWatch
– Specialized and innovative continuous professional training solutions
– Wide range of services to help companies to optimize their positioning, protect and enhance their innovations, conquer new markets and raise public funds.
Operational since September 2015, MabDesign currently has over 290 member companies and its diversity is its strength. MabDesign’s dynamic network includes pharmaceutical and biotech companies, service providers (eg. CROs, CDMOs, etc), professional training actors, high-tech equipment suppliers and specialized consultants
Since 2001 the mission of the SFTCG has been to represent the interests of the factors concerned by the development of new cell and gene therapies, from basic research to clinical applications. Thus, our company’s mission is to promote therapeutic progress in the field of biotherapies, regenerative medicine and gene transfer for diseases of all types, whether genetic or acquired. The objectives of our society is therefore to facilitate the dissemination of scientific information, to promote discussions and exchanges and to play an interface role between the various players in the field.
The role of the SFTCG board and its chair is to foster exchanges with scientists from other fields, industry stakeholders, patient organizations, journal editors and regulatory bodies. Finally, the SFTCG would like to invite all stakeholders with an interest in the development and transfer applications of genes and cell therapy to join us and become an active member of our society today.
